Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > FY results & biz update announced

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Feb 14, 2023 5:46pm

85 Views

Post# 35286236

RE:FY results & biz update announced

Nothing screams comptient like doing it on the last possible day! FML

If I had to speculate, I might guess they had sumitted something to the FDA and were hoping to get it back within the 30 day timeframe, however things took longer than expected, so now their had is forced and they have to do something by the 28th. This is just food for thought, but could explain it.

<< Previous

Bullboard Posts

Next >>

Investors eye Australian gold mining projects amid promising developments